252 related articles for article (PubMed ID: 34684780)
21. Interaction of small molecules with the SARS-CoV-2 papain-like protease: In silico studies and in vitro validation of protease activity inhibition using an enzymatic inhibition assay.
Pitsillou E; Liang J; Ververis K; Hung A; Karagiannis TC
J Mol Graph Model; 2021 May; 104():107851. PubMed ID: 33556646
[TBL] [Abstract][Full Text] [Related]
22. Deciphering inhibitory activity of marine algae Ecklonia cava phlorotannins against SARS CoV-2 main protease: A coupled in-silico docking and molecular dynamics simulation study.
Chakraborty A; Ghosh R; Barik S; Mohapatra SS; Biswas A; Chowdhuri S
Gene; 2024 Oct; 926():148620. PubMed ID: 38821329
[TBL] [Abstract][Full Text] [Related]
23. Identification of potential plant-based inhibitor against viral proteases of SARS-CoV-2 through molecular docking, MM-PBSA binding energy calculations and molecular dynamics simulation.
Gogoi B; Chowdhury P; Goswami N; Gogoi N; Naiya T; Chetia P; Mahanta S; Chetia D; Tanti B; Borah P; Handique PJ
Mol Divers; 2021 Aug; 25(3):1963-1977. PubMed ID: 33856591
[TBL] [Abstract][Full Text] [Related]
24. Identification of novel inhibitors of SARS-CoV-2 main protease (M
Verma S; Patel CN; Chandra M
J Comput Chem; 2021 Oct; 42(26):1861-1872. PubMed ID: 34287986
[TBL] [Abstract][Full Text] [Related]
25. Structure-based virtual screening, in silico docking, ADME properties prediction and molecular dynamics studies for the identification of potential inhibitors against SARS-CoV-2 M
Mohan A; Rendine N; Mohammed MKS; Jeeva A; Ji HF; Talluri VR
Mol Divers; 2022 Jun; 26(3):1645-1661. PubMed ID: 34480682
[TBL] [Abstract][Full Text] [Related]
26. Blue Biotechnology: Computational Screening of
Ibrahim MAA; Abdelrahman AHM; Atia MAM; Mohamed TA; Moustafa MF; Hakami AR; Khalifa SAM; Alhumaydhi FA; Alrumaihi F; Abidi SH; Allemailem KS; Efferth T; Soliman ME; Paré PW; El-Seedi HR; Hegazy MF
Mar Drugs; 2021 Jul; 19(7):. PubMed ID: 34356816
[TBL] [Abstract][Full Text] [Related]
27. Computational Insights on the Potential of Some NSAIDs for Treating COVID-19: Priority Set and Lead Optimization.
Abo Elmaaty A; Hamed MIA; Ismail MI; B Elkaeed E; S Abulkhair H; Khattab M; Al-Karmalawy AA
Molecules; 2021 Jun; 26(12):. PubMed ID: 34205704
[TBL] [Abstract][Full Text] [Related]
28. Anti-HIV and anti-HCV small molecule protease inhibitors in-silico repurposing against SARS-CoV-2 M
Sultan A; Ali R; Ishrat R; Ali S
J Biomol Struct Dyn; 2022; 40(23):12848-12862. PubMed ID: 34569411
[TBL] [Abstract][Full Text] [Related]
29. Potential SARS-CoV-2 protease M
Kouznetsova VL; Huang DZ; Tsigelny IF
Phys Biol; 2021 Feb; 18(2):025001. PubMed ID: 33203811
[TBL] [Abstract][Full Text] [Related]
30. Identification of Pyrazole Derivatives of Usnic Acid as Novel Inhibitor of SARS-CoV-2 Main Protease Through Virtual Screening Approaches.
Roney M; Singh G; Huq AKMM; Forid MS; Ishak WMBW; Rullah K; Aluwi MFFM; Tajuddin SN
Mol Biotechnol; 2024 Apr; 66(4):696-706. PubMed ID: 36752937
[TBL] [Abstract][Full Text] [Related]
31. In Silico Screening of the DrugBank Database to Search for Possible Drugs against SARS-CoV-2.
Cuesta SA; Mora JR; Márquez EA
Molecules; 2021 Feb; 26(4):. PubMed ID: 33669720
[TBL] [Abstract][Full Text] [Related]
32. SARS-CoV-2 M
Citarella A; Scala A; Piperno A; Micale N
Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33921886
[TBL] [Abstract][Full Text] [Related]
33. QSAR Modeling of SARS-CoV M
Alves VM; Bobrowski T; Melo-Filho CC; Korn D; Auerbach S; Schmitt C; Muratov EN; Tropsha A
Mol Inform; 2021 Jan; 40(1):e2000113. PubMed ID: 33405340
[TBL] [Abstract][Full Text] [Related]
34. In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors.
Ibrahim MAA; Abdelrahman AHM; Allemailem KS; Almatroudi A; Moustafa MF; Hegazy MF
Protein J; 2021 Jun; 40(3):296-309. PubMed ID: 33387249
[TBL] [Abstract][Full Text] [Related]
35. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
36. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
37. Iterated Virtual Screening-Assisted Antiviral and Enzyme Inhibition Assays Reveal the Discovery of Novel Promising Anti-SARS-CoV-2 with Dual Activity.
Hamdy R; Fayed B; Mostafa A; Shama NMA; Mahmoud SH; Mehta CH; Nayak Y; M Soliman SS
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445763
[TBL] [Abstract][Full Text] [Related]
38. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
39. Conserved interactions required for inhibition of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Shitrit A; Zaidman D; Kalid O; Bloch I; Doron D; Yarnizky T; Buch I; Segev I; Ben-Zeev E; Segev E; Kobiler O
Sci Rep; 2020 Nov; 10(1):20808. PubMed ID: 33257760
[TBL] [Abstract][Full Text] [Related]
40. Searching possible SARS-CoV-2 main protease inhibitors in constituents from herbal medicines using
Rasul HO; Thomas NV; Ghafour DD; Aziz BK; Salgado M G; Mendoza-Huizar LH; Candia LG
J Biomol Struct Dyn; 2024 May; 42(8):4234-4248. PubMed ID: 37349945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
